Skip to main content
Medartis Holding AG logo

Medartis Holding AG — Investor Relations & Filings

Ticker · MED ISIN · CH0386200239 LEI · 506700VUSP6HG3F28846 SW Manufacturing
Open in API
Filings indexed 101 across all filing types
Latest filing 2025-07-30 Report Publication Anno…
Country CH Switzerland
Listing SW MED

About Medartis Holding AG

https://www.medartis.com/

Medartis Holding AG is a medical device company that develops, manufactures, and distributes implant solutions for the surgical fixation of bone fractures. The company provides precision-engineered system solutions, including titanium screws, plates, and surgical instruments. Its primary focus is on osteosynthesis for the upper and lower extremities, as well as for cranio-maxillofacial surgery. Medartis offers comprehensive solutions designed to support surgeons and facilitate optimal patient care in fracture fixation procedures.

Recent filings

Filing Released Lang Actions
Medartis 2025 half-year results webcast
Report Publication Announcement Classification · 100% confidence The document is an invitation to a future webcast regarding the company's 2025 half-year results. It explicitly states that the actual reports (press release, half-year report, and presentation slides) will be published on a future date (19 August 2025). Since the document is an announcement regarding the timing and release of future reports rather than the reports themselves, it falls under the Report Publication Announcement (RPA) category.
2025-07-30 English
Medartis acquires remaining 53% stake in KeriMedical
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated July 17, 2025, detailing Medartis Group's decision to acquire the remaining 53% stake in KeriMedical for CHF 99 million, following FDA approval of a product. This announcement concerns a significant corporate transaction, specifically an acquisition/takeover activity. This aligns directly with the definition for M&A Activity (TAR). It is not a full financial report (10-K or IR), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific corporate action (M&A).
2025-07-17 English
Medartis acquires remaining 53% stake in KeriMedical
M&A Activity Classification · 99% confidence The document is an 'Ad hoc announcement pursuant to Art. 53 LR' detailing Medartis Group's acquisition of the remaining 53% stake in KeriMedical for CHF 99 million plus earn-outs. This type of announcement, concerning a significant corporate transaction (Mergers & Acquisitions), is typically classified under 'TAR' (M&A Activity) if it were the primary document. However, the text explicitly mentions that Medartis will publish its financial results for H1 2025 on August 19, 2025, and provide further details then. The current document is a press release announcing a major corporate event (acquisition) and is not a full financial report (like 10-K or IR) or a management discussion (MDA). Since the core subject is a takeover/acquisition, the most fitting category is TAR (M&A Activity). It is a direct announcement of the transaction, not just a notice that a report is coming, so RPA/RNS is less appropriate than TAR.
2025-07-17 English
Medartis erwirbt restliche 53 % der Anteile an KeriMedical
M&A Activity Classification · 99% confidence The document is titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and announces that Medartis Holding AG is acquiring the remaining 53% stake in KeriMedical. This is a significant corporate event related to a change in ownership/control, which falls under Mergers & Acquisitions (M&A) activity. The filing type definition for M&A Activity is 'TAR' (Merger Proposals or Takeover Bids). Although it is an ad-hoc announcement, the content is the core M&A news itself, not just an announcement that a report will follow later. The document explicitly details the transaction terms (CHF 99 million cash plus earn-outs) and strategic rationale. Therefore, TAR is the most appropriate classification.
2025-07-17 German
Medartis delivers 12% core sales growth in 2024 and improves its core EBITDA margin from 17% to 19%
Earnings Release Classification · 100% confidence The document is a press release dated March 18, 2025, reporting 'FULL-YEAR 2024 KEY FINANCIALS' including Net sales, EBITDA, and EBIT comparisons between FY 2024 and FY 2023. It details performance by region and product category, discusses management commentary, and announces strategic moves (like the acquisition of NeoOrtho and Avenger Radial Head System). This content structure—comprehensive annual financial highlights released early in the year—is characteristic of an Earnings Release (ER) or potentially an Interim Report (IR) if it were mid-year. Since it covers the *full year* (FY 2024) and provides key financial metrics and management outlook, it fits the definition of an Earnings Release (ER) which is the initial announcement of periodical financial results. It is too detailed for a simple RPA, and while it contains annual data, it is presented as a press release summary rather than the full, audited 10-K document, making ER the most appropriate classification for this initial results announcement. FY 2024
2025-03-19 English
Medartis delivers 12% core sales growth in 2024 and improves its core EBITDA margin from 17% to 19%
Earnings Release Classification · 100% confidence The document is a press release dated March 18, 2025, reporting 'FULL-YEAR 2024 KEY FINANCIALS' including Net sales, EBITDA, and EBIT comparisons between FY 2024 and FY 2023. It details performance by region and product category, discusses management commentary, and announces strategic moves (like the acquisition of NeoOrtho and Avenger Radial Head System). This content structure—comprehensive annual financial highlights released early in the year—is characteristic of an Earnings Release (ER) or potentially an Interim Report (IR) if it were mid-year. Since it covers the *full year* (FY 2024) and provides key financial metrics and management outlook, it fits the definition of an Earnings Release (ER) which is the initial announcement of periodical financial results. It is too detailed for a simple RPA, and while it contains annual data, it is presented as a press release summary rather than the full, audited 10-K document, making ER the most appropriate classification for this initial results announcement. FY 2024
2025-03-18 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.